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Two new spectrophotometric methods using permanganate as the oxidimetric reagent for the determination 
of olanzapine (OLP) were developed and validated as per the current ICH guidelines. The methods 
involved the addition of known excess of permanganate to OLP in either acid or alkaline medium 
followed by the determination of unreacted permanganate at 550 nm (method A) or bluish-green color 
of manganate at 610 nm (method B). The decrease in absorbance in method A or increase in absorbance 
in method B as a function of concentration of OLP was measured and related to OLP concentration. 
Under optimized conditions, Beer’s law was obeyed over the ranges 2.0 to 20 and 1.0 to 10 µg mL-1 
in method A and method B, respectively. The calculated molar absorptivity values were 1.34 x 104 and 
2.54 x 104 l mol-1cm-1 for method A and method B respectively, and the respective Sandell sensitivities 
were 0.0233 and 0.0123 µg cm-2. The LOD and LOQ for method A were calculated to be 0.37 and 1.13 
µg mL-1and the corresponding values for method B were 0.16 and 0.48 µg mL-1. Intermediate precision, 
expressed as RSD was in the range 0.51 to 2.66 %, and accuracy, expressed as relative error ranged from 
0.79 to 2.24 %. The proposed methods were successfully applied to the assay of OLP in commercial 
tablets with mean percentage recoveries of 102 ±1.59 % (method A) and 101 ±1.53 % (method B). The 
accuracy and reliability of the methods were further confirmed by performing recovery tests via standard 
addition procedure.
Uniterms: Olanzapine/determination. Spectrophotometry. Permanganate. Pharmaceuticals.
Dois métodos espectrofotométricos novos, usando o permanganato como o reagente oxidimétrico para 
a determinação da olanzapina (OLP) foram utilizados e validados de acordo com as diretrizes atuais do 
ICH. Os métodos envolveram a adição  de excesso conhecido de permanganato à OLP em meio ácido 
ou alcalino, determinando-se o permanganato que não reagiu em 550 nm (método A), ou pela cor verde-
azulada do manganato a 610 nm (método B). A diminuição da absorbância no método A ou o aumento da 
absorbância no método B, em função da concentração de OLP, foi medida e relacionada à concentração 
de OLP. Sob condições otimizadas, a lei de Beer foi obedecida, nas faixas de concentração  de 2,0 a 20 
e 1,0 a 10 ao µg mL-1, no método A e no método B, respectivamente. Os valores de absortividade molar 
foram de 1,34 x 104 e 2,54 x 104 l mol-1cm-1 para o método A e para o método B, respectivamente, e 
as sensibilidades respectivas de Sandell foram de 0,0233 e 0,0123 µg cm-2. Os LOD e os LOQ para o 
método A calculados foram 0,37 e 1,13 mg mL-1e os valores correspondentes para o método B foram 
0,16 e 0,48 µg mL-1. A precisão intermediária, expressa como RSD, encontrou-se na faixa de 0,51 a 
2,66%, e a exatidão, expressa como o erro relativo, variou de 0,79 a 2,24%. Os métodos propostos foram 
aplicados com sucesso ao ensaio de OLP em comprimidos comerciais, com porcentagens médias de 
recuperação de 102± 1,59% (método A) e de 101± 1,53% (método B). A exatidão e a confiabilidade dos 
métodos foram confirmadas executando testes de recuperação através de procedimento padrão de adição.
Uniterms: Olanzapina/determinação. Espectrofotometria. Permanganato. Produtos farmacêuticos.
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INTRODUCTION
Olanzapine (OLP), chemically known as 2-methyl-
10-(4-methyl-piperazin-1-yl)-4H-3-thia-4,9-diaza-
benzo[f]azulene (Figure 1), is an atypical antipsychotic 
drug that belongs to the thienobenzodiazepine class. It 
shows high receptor affinity binding in vitro at serotonin, 
dopamine, muscarinic and histamine receptors. Since its 
introduction in 1997, it has been approved in 84 countries 
for treating schizophrenia and related disorders (Shen, 
1999).
Several analytical methods have been reported 
for the determination of OLP in biological fluids and in 
pharmaceutical preparations, and they include high per-
formance liquid chromatography (HPLC) with ultraviolet 
(Olesen et al., 1998; Boulton et al., 2001; Harald et al., 
2001; Concetta et al., 2006; Dusci et al., 2002; Olesen et 
al., 2001; Raggi et al., 2000; Saracino et al., 2007; Shah 
et al., 2007; Reddy et al., 2007; Xuejun et al., 2004); 
electrochemical (Saracino et al., 2006; Raggi et al., 
2000; Bao, Potts., 2001; Raggi et al., 2001; Kasper et 
al., 1999) or mass spectrometric (Thieme, Sachs., 2003; 
Berna et al., 2002; Titier et al., 2003; Dusci et al., 2002) 
detection, gas chromatography (Sabbioni et al., 2004), 
capillary zone electrophoresis (Raggi et al., 2000), UV-
spectrophotometry and non-aqueous titrimetry (Firdous 
et al., 2005). However, there are only three reports on the 
visible spectrophotometric methods (Jasinska, Nalewajko, 
2004; Mohamed, 2008; Krebs et al., 2006) based on redox 
reaction using hexacyanoferrate (III), cerium (IV), N-
bromosuccinimide (NBS) or potassium iodate. However, 
these methods suffer from one or the other disadvantage 
such as poor sensitivity, unstable color and rigid experi-
mental conditions (Table I).
The aim of the present work is to develop simple, 
sensitive and cost-effective spectrophotometric methods 
for the determination of OLP in pharmaceutical formula-
tions. The methods make use of potassium permanganate 
as the oxidimetric reagent, and have been demonstrated 
to be superior to the existing spectrophotometric me-
thods in terms of sensitivity, color stability, working 
conditions, and accuracy and precision. We have found 
that potassium permanganate has earlier been used in 
pharmaceutical analysis in the determination of thio-
xanthines, for example (Tammilehto, 1980), isoniazid 
(Murugesan, Venkappayya, 1983) methyl thiouracil 
(Kucharski, Sikorska-Tomica, 1982) chloramphenicol 
(Fedchenko, 1985) amidopyrine (Stepnayuk and Bala-
gorazumnya, 1989), valdecoxib (Suganthi et al., 2006), 
nicotine (Al-Tamrah, 1999) tramadol HCl (Abdellatef, 
2002) cefuroxime (Reddy et al., 2002), diloxamide (Al-
Ghanman, Belal., 2001) and pentacozine (Sastry et al., 
1998), to mention a few.
In our studies OLP was found to react with per-
manganate in H
2
SO
4
 medium consuming the oxidant in 
proportion to its concentration. This reaction was used 
for the indirect assay of OLP by measuring the decrease 
in the absorbance at 550 nm as a function of the OLP 
concentration. On the other hand, in alkaline medium, 
the reaction yielded a bluish-green manganate with a 
λ
max
 at 610 nm. This color reaction was studied for the 
direct spectrophotometric determination of the drug. 
Optimum conditions were established and both the me-
thods were validated for linearity, sensitivity, accuracy 
and precision as well as robustness and ruggedness. The 
validated methods when applied to the determination of 
OLP in tablets yielded results which were in agreement 
with the label claim.
MATERIAL AND METHODS
Apparatus
Absorbance measurements were made with a Systro-
nics model 106 digital spectrophotometer equipped with 
1 cm matched quartz cells.
Reagents and standards
All chemicals used were of analytical grade and 
solutions were made in distilled water.
Potassium permanganate (600 µg mL-1)
An approximately 0.002 M solution was prepared by 
dissolving 79.00 mg of KMnO
4
 (Merck, Mumbai, India) 
in water and diluting to 250 mL in a calibrated flask, and 
standardized using H.A Bright’s procedure (Vogel, 1961). 
The standard solution was then diluted appropriately with 
water to get 600 µg mL-1 working concentration for me-
thod A. A separate 0.2 % aqueous solution was prepared 
for use in method B.
FIGURE 1 - Structure of olanzapine
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Sulphuric acid (0.1 and 2 M)
Concentrated acid (S.D. Fine Chem, Mumbai, India, 
sp. gr. 1.84) was appropriately diluted with water to get 
the required concentrations.
Sodium hydroxide (1 M)
Prepared by dissolving 4 g of the chemical (Merck, 
Mumbai, India) in 100 mL of water.
Standard OLP solution
Pharmaceutical grade OLP certified to be 99.85 % pure 
was kindly provided by Cipla India Ltd., Mumbai, India; and 
was used as received. A 500 µg mL-1 stock standard solution 
was prepared by dissolving accurately weighed 50 mg of pure 
OLP in 0.1 M H
2
SO
4
 and diluting to the mark in a 100 mL ca-
librated flask with the same acid. It was subsequently diluted 
to 50 µg mL-1 OLP for method A. Twenty mg of OLP were 
weighed separately and dissolved in 5 mL of 0.5 M acetic 
acid and diluted to 100 mL in a calibrated flask with water. 
The solution was then diluted with water to get a working 
concentration of 20 µg mL-1 for use in method B.
Tablets
Three brands of tablets claimed to contain 2.5, 5.0 
and 20 mg OLP per tablet were purchased from local ma-
rket for investigation.
TABLE I - Comparison of the performance characteristics of the present methods with the published methods
Sl. No. Reagent/s 
used
Methodology l
max
(nm)
Linear range
(µg mL-1)
LOQ
(µg mL-1)
Remarks Ref.
1. a) Hexacyano 
ferrate (III)
Unreacted oxidant 
measured
425 2.5-40.0 - Reaction requires 1:1 mixture 
of H
2
SO
4
 and H
3
PO
4
,  
Jasinska and 
Nalewajko 
2004
b) Hexacyano 
ferrate (III)
Radical cation 
measured
540 0.5-250 Contact time 60 min required. 
c) Cerium (IV) 
sulphate
540 0.05-300 FIA assembly required
2.  a) KIO
3
Initial rate of 
formation of radical 
cation measured
537 Up to 4.0 Scrupulous control of 
experimental variables and 
special equipment for kinetic 
measurement required.
Mohamed 
2008
b) KIO
3
Maximum 
absorbance 
measured
537 Up to 7.0
3. a) NBS  Radical cation 
measured   
532    10-120 
(ε = 4.2x104)    
7.0     Uses 1:1 miture of H
2
SO
4
 and 
H
3
PO
4
 as the reaction medium, 
colour stable for only 30 s.
Krebs 
et al., 
2006
b) NBS-
Celestine blue
Unbleached dye 
colour measured
538 0.5-6.0 
(ε = 6.41x104)
0.30 High acidic conditions required
c) Cerium(IV)-
Celestine blue
0.6-3.0 
(ε = 1.48 x 105)
0.37
4.  a) KMnO
4
 
(acid medium) 
Unreacted 
KMnO
4
 
measured
550 2.0-20.0 
(ε = 1.34 x 104)
1.13 Mild acidic/alkaline conditions 
used; stable colour measured, 
wide linear dynamic ranges 
and fairly sensitive, simple 
instrument employed.
Present 
work
b) KMnO
4
-
Alkaline 
medium
Bluish-green 
manganate 
measured.
610 1.0-10.0 
(ε = 2.54 x 104)
0.48
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Procedure
Method A
Aliquots of standard OLP solution (50 µg mL-1) 
in the range 0.0-4.0 mL were accurately measured and 
transferred to a series of 10 mL calibrated flasks and the 
volume was adjusted to 4.0 mL with 0.1 M H
2
SO
4
. Two mL 
of 2 M H
2
SO
4
 were added to each flask followed by 1 mL 
of 600 µg mL-1 KMnO
4
 solution. The content was mixed 
and the flasks were let stand for 15 min before diluting to 
the mark with water. The absorbance of each solution was 
measured at 550 nm against a reagent blank.
Method B
Known volumes of standard OLP solution (0.0, 
1.0,…..5.0 mL) were accurately delivered into a series of 
10 mL calibrated flasks and the volumes were adjusted to 
5.0 mL with water. To each flask were added 1 mL each of 
1 M NaOH and 0.2 % KMnO
4
 solutions. The content was 
mixed well and flasks were allowed to stand for 15 min 
with occasional shaking. Then, the volume was made up to 
the mark with water and absorbance measured at 610 nm 
against a reagent blank.
Calibration graphs were prepared by plotting either 
the decreasing absorbance values in method A or increa-
sing absorbance values in method B versus concentrations 
of OLP. The unknown concentration was read from the 
respective calibration graph or deduced from the regres-
sion equation desired using the Beer’s law data.
Procedure for tablets
Twenty tablets were weighed accurately and pulve-
rized. A quantity of the powder containing 20 mg of OLP 
was accurately weighed into a 100 mL calibrated flask, 
added 60 mL of 0.1 M H
2
SO
4
 and shaken for 20 min. Then, 
the volume was diluted to the mark with 0.1 M H
2
SO
4
, 
mixed and filtered using a Whatman No 42 filter paper. 
First 10 mL of the filtrate were discarded and a suitable 
aliquot of the subsequent portion (200 µg mL-1 in OLP) 
was diluted with 0.1 M H
2
SO
4
 to obtain 50 µg mL-1 solu-
tion and the analysis was completed using the procedure 
described earlier (method A). However, for method B, a 
portion of the tablet powder equivalent to 20 mg of OLP 
was accurately weighed into a 100 mL beaker. The powder 
was extracted with three 10 mL portions of chloroform and 
each time the extract was filtered with a Whatman No 42 
filter paper. The filtrate was collected in 100 mL calibrated 
flask, chloroform was evaporated over a water bath and the 
residue was dissolved in 5 mL 0.5 M acetic acid and the 
solution was diluted to the mark with water. The solution 
was appropriately diluted before applying the procedure 
for the assay of drug content.
Placebo for analysis
A placebo blank of the composition: starch (10 mg), 
acacia (15 mg), hydroxyl cellulose ( 10 mg), sodium citrate 
(10 mg), talc (20 mg), magnesium stearate (15 mg) and 
sodium alginate (10 mg) was made and its solution was 
prepared as described under ‘tablets’, and then subjected 
to analysis.
RESULTS AND DISCUSSION
The proposed methods are based on the redox reac-
tion between permanganate and OLP in acid (method A) 
or in alkali (method B) medium. In method A, a known 
excess of KMnO
4 
was added to OLP in H
2
SO
4 
medium 
followed by the determination of the residual oxidant by 
measuring its absorbance at 550 nm. The decrease in ab-
sorbance at 550 nm with respect to the reagent blank was 
taken as the measure of OLP concentration. In method B, 
K
2
MnO
4
 resulting from the reduction of KMnO
4
 by OLP 
in NaOH medium was measured at 610 nm and related to 
OLP concentration. The possible reaction scheme of both 
the methods is given in Scheme 1 and Scheme 2.
Method development: Optimization of 
experimental variables
Method A
Preliminary experiments were performed to de-
termine the permanganate concentration which would 
give a reasonable maximum absorbance at 550 nm and 
in H
2
SO
4
 medium; and this was found to be 60 µg mL-1 
(0.811 absorbance unit). Hence, different concentrations 
of OLP were reacted with 1 mL of 600 µg mL-1 KMnO
4
 
in H
2
SO
4
 medium, and after elapsed the contact time, the 
absorbance of the residual permanganate was measured 
and related to OLP concentration.
When a fixed concentration of KMnO
4
 (60 µg mL-1) 
was reacted with varying concentrations of OLP, the for-
mer was consumed in proportion to OLP concentration 
and there occurred a concomitant fall in the concentration 
of KMnO
4
 as shown by the decreasing absorbance values 
at 550 nm with increase in the OLP concentration. This 
is depicted in Figure. 2. This facilitated the evaluation of 
the linear range over which the method is applicable to the 
determination of OLP.
Since oxidation reactions with permanganate are 
usually performed in H
2
SO
4 
medium (Basset et al., 1978), 
Determination of olanzapine by spectrophotometry using permanganate 543
the reaction of the oxidant with the drug was carried out in 
H
2
SO
4
 medium. Experiments were performed with H
2
SO
4
 
concentrations in the range 0.5-1.5 M and it was found 
that maximum and constant absorbance readings were 
obtained in the range studied (Figure 3a). Hence, 2 mL of 
2 M H
2
SO
4
 in a total volume of ~7 mL was fixed as the 
optimum. The reaction time selected for the recommended 
method was fixed by carrying out the experiment using 
10 µg mL-1 OLP. Maximum absorbance was obtained in 
15 min and it remained constant for the next 45 min (Fi-
gure 3b) at room temperature.
Method B
This method is based on the reduction of perman-
ganate to manganate by OLP in the presence of NaOH, 
Scheme 1 - Method A. Reaction scheme.
Scheme 2 - Method B. Reaction scheme.
FIGURE 2 - Effect of OLP concentration on the absorbance 
of 60 µg mL-1 KMnO
4
 (A.0.0; B.5.0; C.10.0; D.15.0 and 
E.20 µg mL-1 OLP).
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thereby producing the reduced species - the bluish-green 
colored chromogen (Mann, Sounders, 1974; Sharma, 
1994) having the absorption maximum at 610 nm (Figure 
4). The formation of the colored product and the sensi-
tivity of the reaction were found to be influenced by the 
alkali and permanganate concentrations. Maximum and 
constant absorbance readings were observed when an 
overall NaOH concentration of 0.06-0.5 M was main-
tained at a drug concentration of 6 µg mL-1. Two mL of 
2 M NaOH in a total volume of 7 mL were hence used 
for the redox reaction (Figure. 5a). The reaction was so-
mewhat rapid compared to method A, taking 10 min for 
completion, and the bluish-green manganate color was 
stable for 40 min thereafter (Figure 5b). When a separate 
experiment was conducted to study the permanganate 
concentration, it was found that maximum absorbance 
associated with a minimum blank reading was obtained 
when 1 mL of 0.2 % KMnO
4
 in a total volume of 10 mL 
was used. Higher concentrations of permanganate, no 
doubt, resulted in increased sensitivity but the blank 
absorbance simultaneously showed an increasing trend.
Method validation
· Linearity, sensitivity, limits of detection and quanti-
fication
Calibration graphs were constructed from nine 
and six points covering the concentration ranges 2.0-
20.0 and 1-10 µg mL-1 for method A and method B, 
respectively (Figure 6). In method A, Beer’s law was 
obeyed in the inverse manner. Regression analysis of 
the Beer’s law data indicated a linear relationship be-
tween absorbance and concentration (Table II), which is 
corroborated by high values (close to unity) of the cor-
relation coefficients. The small values of the variance 
speak about the negligible scattering of the calibration 
data points around the line of regressions for both the 
proposed procedures. The significance of correlation 
coefficients was evaluated by calculating the t-values 
using the following formula (Miller, Miller, 2000):
21
2
r
nr
t
−
−
=
The calculated values were found to be 30.26 and 
48.45 for method A and method B, respectively. Thus, 
FIGURE 3 - Effect of H
2
SO
4
 concentration and reaction time (method A). (a). Effect of H
2
SO
4
 concentration (10 µg mL-1 OLP). 
(b)..Effect of reaction time and stability of the coloured species.
FIGURE 4 - Absorption spectra for method B (a. reagent blank; 
b. coloured species produced for 8 µg mL-1 OLP).
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it can be concluded that there is significant relationship 
between the concentration of OLP and the parameters 
used in the development of regression equations.
 The calculated molar absorptivity and Sandell 
sensitivity (Zavis et al., 1976) values are summarized 
in Table II. The limits of detection (LOD) and quanti-
fication (LOQ), calculated according to the ICH (ICH 
guidelines 1996) guidelines using the formulae: 
LOD = 3.3 S/b and LOQ = 10 S/b, (where S is 
the standard deviation of seven blank absorbance va-
lues, and b is the slope of the calibration plot) are also 
summarized in Table II. The high values of ε and low 
values of Sandell sensitivity and LOD indicate the high 
sensitivity of the proposed methods. The reaction stoi-
chiometry for method B was determined by the Job’s 
method of continuous variations and was found to be 
1:4 (OLP:KMnO
4
).
· Precision and accuracy
The assays described under “general procedures” 
were repeated seven times within the day to deter-
mine the repeatability (intra-day precision) and six 
times on different days to determine the intermediate 
precision (inter-day precision) of the methods. These 
assays were performed for three levels of analyte. 
The results of this study are summarized in Table III. 
The percentage relative standard deviation (%RSD) 
values were <2 % (intra-day) and <3 % (inter-day) 
indicating high precision of the methods. The accu-
racy of the methods was determined by the percent 
mean deviation from known concentration, bias % 
= [(Concentration found - known concentration) x 
100/known concentration]. 
Bias was calculated at each concentration and 
these results are also presented in Table III.
FIGURE 5 - Effect of NaOH concentration and standing time. (a). Effect of NaOH concentration (6 µg mL-1 OLP). (b). Effect of 
reaction time and stability of the coloured species.
FIGURE 6 - Calibration curves for method A and method B. 
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· Selectivity
A systematic study was performed to determine 
the effect of matrix by analyzing the placebo blank and 
synthetic mixture containing OLP. A placebo blank of 
the composition described earlier was prepared and 
analyzed. The absorbance of the placebo solution in each 
TABLE II - Sensitivity and regression parameters
Parameter Method A Method B
l
max
, nm 550 610
Color stability, min. 45 40
Linear range, µg mL-1 2.0-20.0 1.0-10.0
Molar absorptivity(ε), 
L mol-1 cm-1
1.34 x 104 2.54 x 104
Sandell sensitivity*, µg cm-2 0.0233 0.0123
Limit of detection (LOD), 
mg mL-1 0.37 0.16
Limit of quantification (LOQ), 
mg mL-1 1.13 0.48
Regression equation, Y**
Intercept (a) 0.8111 0.0310
Slope (b) -0.0411 0.0965
Standard deviation of a (S
a
) 0.0998 0.0998
± tS
a
/√n 0.077 0.071
Standard deviation of b (S
b
) 0.0052 0.0111
± tS
b
/√n 0.004 0.008
Variance (S
a
2) 9.96 x 10-3 9.96 x 10-3
Regression coefficient (r) -0.9962 0.9983
*Limit of determination as the weight in µg per mL of 
solution, which corresponds to an
absorbance of A = 0.001 measured in a cuvette of cross-
sectional area 1 cm2 and l = 1 cm. **Y=a+bX, Where Y is the 
absorbance, X is concentration in µg mL-1, a is intercept, b 
is slope, ± tS
a
/√n = confidence limit for intercept, ± tS
b
/√n = 
confidence limit for slope.
TABLE III - Evaluation of accuracy and precision
Method
OLP taken, 
µg mL-1
Intra-day accuracy and precision (n=7) Inter-day accuracy and precision (n=6)
OLP found µg 
mL-1±CL
%RE %RSD
OLP found µg 
mL-1±CL
%RE %RSD
A
5.00
10.0
15.0
4.92±0.08
10.2±0.11
14.8±0.09
1.60
2.00
1.33
1.76
1.13
0.67
4.89±0.12
10.02±0.22
15.28±0.28
2.20
0.20
1.87
2.66
2.34
1.97
B
2.00
4.00
6.00
2.02±0.01
4.05±0.06
5.90±0.09
1.00
1.25
1.67
0.51
1.50
1.68
2.03±0.02
3.94±0.09
6.12±0.12
1.50
1.50
2.00
1.24
2.37
2.08
%RE. Percent relative error, %RSD. relative standard deviation and CL. Confidence limits were calculated from: CL = ± tS/√n. 
(t = 2.44 for six degrees of freedom at the 95% confidence level; S = standard deviation and n = number of measurements).
case was almost equal to the intercept of the calibration 
graph, which revealed no interference. To assess the 
role of the inactive ingredients on the assay of OLP, a 
synthetic mixture was separately prepared by adding 20 
mg of OLP to the placebo mentioned above. The drug 
was extracted and solution prepared as described under 
the general procedure for tablets. The solution after 
appropriate dilution were analyzed following the recom-
mended procedures. The absorbance resulting from 10 µg 
mL-1 (method A) and 6 µg mL-1 (method B) were nearly 
the same as those obtained for pure OLP solutions of 
identical concentrations. This unequivocally demonstra-
ted the non-interference of the inactive ingredients in the 
assay of OLP. Further, the slopes of the calibration plots 
prepared from the synthetic mixture solutions were about 
the same as those prepared from pure drug solutions. 
In method B (alkaline medium) a strong interference 
was noticed from some tablet excipients causing erra-
tic results. To overcome this interference, after several 
trials, it was found that OLP in the synthetic mixture or 
the tablet should be extracted with chloroform, before 
applying the method following the steps involved in the 
assay procedure.
Robustness and ruggedness
To determine the robustness of the methods, two 
experimental variables, acid/alkaline concentration and 
reaction time, were altered deliberately in small incre-
ments. Intermediate precision expressed as %RSD was 
calculated and found to be <1 %. Method ruggedness was 
demonstrated having the analysis done by four analysts, 
and also by a single analyst performing analysis on three 
different instruments in the same laboratory. Intermediate 
precision values in both instances were in the range 0.85-
3.06% indicating acceptable ruggedness. These results are 
summarized in Table IV
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TABLE IV - Method robustness and ruggedness expressed as intermediate precision (% RSD)
Method
OLP taken
µg/mL-1
Robustness Ruggedness
Parameter altered
Inter-Analysts
(% RSD)
Inter-instruments
 (% RSD)Reaction time*
H
2
SO
4
/NaOH 
concentration**
A
5.00
10.0
15.0
0.76
0.82
0.97
0.66
0.74
0.52
1.04
0.86
0.92
2.74
3.05
2.46
B
2.00
4.00
6.00
0.56
0.83
0.78
0.66
0.48
0.78
0.78
0.92
0.85
2.44
3.16
2.58
*In method A, the reaction times were 13, 15 and 17 min, and the same were 8, 10 and 12 min in method B. **In method A, H
2
SO
4
 
concentrations were 0.5, 0.6 and 0.7 M, and NaOH concentrations in method B were 0.1, 0.2 and 0.3 M.
TABLE V - Results of analysis of tablets by the proposed methods and statistical comparison of the results with the reference method.
Tablet brand 
nameψ
Nominal amount 
(mg/tablet)
Found (mg ± CL)
Found* (Percent of label claim ± SD)
Reference 
method
Method A Method B
Method A Method B
Olimelt-2.5a 2.5 2.60±0.04 2.57±0.03 103.6±0.52
104.1±1.26
t=0.89
F=5.87
102.8±0.96
t=1.71
F=3.41
Oleanz-5b 5.0 4.94±0.08 4.90±0.07 97.48±0.75
98.73±1.35
t=1.88
F=3.24
98.04±1.08
t=0.97
F=2.07
Oleanz-20c 20.0 19.8±0.27 20.0±0.33 98.54±0.68
99.14±1.09
t=1.07
F=2.57
100.1±1.35
t=2.43
F=3.94
*Mean value of 5 determination. ψMarketed by : aRanbaxy Laboratories Ltd (Solus), bCipla India Pvt Ltd (Mumbai), 
cSunPharmaceuticals Industries Ltd, Mumbai, India.
Application
The proposed methods are applied for the quantifica-
tion of OLP in commercial tablets. The results were com-
pared with those obtained using a published non-aqueous 
titrimetric method (Firdous et al., 2005). Statistical analy-
sis of the results did not detect any significant difference 
between the performance of the proposed methods and 
reference titrimetric method, with respect to accuracy and 
precision as revealed by the Student’s t-value and variance 
ratio F-value (Inczedy et al., 1998). The results of assay 
are given in Table V.
Recovery study
To further assess the accuracy of the methods, 
recovery experiments were performed by applying the 
standard-addition technique. The recovery was assessed 
by determining the agreement between the measured 
standard concentration and added known concentration to 
the sample. The test was done by spiking the pre-analyzed 
tablet powder with pure OLP at three different levels (50, 
100 and 150%) of the content present in the tablet powder 
(taken), and the total was found by the proposed methods. 
Each test was repeated three times. In all the cases, the 
recovery percentage values ranged between 99.4 and 
104.1%, with relative standard deviation in the range 1.35-
1.78 %. Closeness of the results to 100 % showed the fairly 
good accuracy of the methods (Table VI).
CONCLUSIONS
The methods proposed herein, based on the use of 
spectrophotometry with permanganate, can reliably deter-
mine olanzapine in pharmaceuticals, with good accuracy 
and precision. Furthermore, the methods are more sensitive, 
as compared to many published spectrophotometric metho-
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ds (Jasinska, Nalewajko., 2004; Mohamed., 2008; Krebs 
et al., 2006) and also some HPLC methods (Olesen et al., 
1998; Harald et al., 2001; Concetta et al., 2006; Dusci et al., 
2002; Olesen et al., 2001; Raggi et al., 2001; Raggi et al., 
2000; Shah et al., 2007; Reddy et al., 2007; Xuejun et al., 
2004). The methods are simpler as compared to published 
methods (Jasinska, Nalewajko, 2004; Mohamed, 2008; 
Krebs et al., 2006) with respect to experimental conditions, 
instrumental setup and the stability of the measured species. 
An all important advantage is the cost-effectiveness, since 
analysis can be performed with an inexpensive instrument 
as compared to methods (Jasinska, Nalewajko, 2004; Moha-
med, 2008) which require expensive devices and/or reagents 
(Table I). The methods are rapid and allow the determination 
of the drug in tablets without any interference from the 
common tablet excipients. The limitation of method B (in 
alkaline medium) is that it cannot be applied directly to the 
tablets, and involves extraction of the drug into chloroform 
and evaporation of the organic solvent before other steps 
are applied for the assay.
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